CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 298 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00895011
NCT00895011Phase 3Completed

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of the Safety and Efficacy of Avanafil in the Treatment of Erectile Dysfunction Following Bilateral Nerve-Sparing Radical Prostatectomy

VIVUS LLC·interventional·Posted May 7, 2009·Updated Oct 1, 2012

In Brief

A Phase 3 clinical trial evaluating Placebo and Avanafil for Erectile Dysfunction. Completed, enrolled 298 participants across 51 sites.

Detailed Summary

The objectives of this study are to evaluate the safety and efficacy of two doses of avanafil in the treatment of adult males for erectile dysfunction following bilateral nerve-sparing radical prostatectomy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 7, 2009
Enrollment StartApr 1, 2009
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 17.2 years ago

Interventions

Placebodrug

One dose 30 minutes prior to initiation of sexual activity

Avanafildrug

One dose 30 minutes prior to initiation of sexual activity

Avanafildrug

One dose 30 minutes prior to initiation of sexual activity